FDA Unleashes Fast Lane: Pilot Program Shortens Drug Testing Timelines

The FDA on Tuesday opened applications for a pilot program to shorten drug approval timelines, a cornerstone of the "Operation TrialBlazer" initiative aimed at helping the U.S. compete with biotech powerhouses like China and Australia. The program targets the initial phase where companies move from lab to human testing, promising to cut years from the current U.S. pathway. "Too often, the U.S. pathway can be measured in years, while other countries' pathways are measured in...